Entero Therapeutics, Inc. (ENTO)
NASDAQ: ENTO · Real-Time Price · USD
0.401
-0.007 (-1.74%)
At close: Nov 20, 2024, 4:00 PM
0.420
+0.019 (4.76%)
Pre-market: Nov 21, 2024, 7:07 AM EST
Entero Therapeutics Employees
Entero Therapeutics had 9 employees as of December 31, 2023. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
n/a
Profits / Employee
-$1,127,763
Market Cap
1.30M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| China SXT Pharmaceuticals | 75 |
| Helius Medical Technologies | 22 |
| Tenon Medical | 21 |
| TFF Pharmaceuticals | 19 |
| Catheter Precision | 14 |
| Altamira Therapeutics | 10 |
| Revelation Biosciences | 9 |
| SCWorx | 7 |
ENTO News
- 6 days ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - Accesswire
- 6 days ago - ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO - Business Wire
- 8 days ago - Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company - GlobeNewsWire
- 6 weeks ago - Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board - Business Wire
- 3 months ago - Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q - GlobeNewsWire
- 4 months ago - Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - GlobeNewsWire
- 5 months ago - Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease - GlobeNewsWire
- 6 months ago - Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention - GlobeNewsWire